ASMB (Assembly Biosciences, Inc.) Projected Sales Volume

ASMB (Assembly Biosciences) - company brandmark

The future sales trend for Assembly Biosciences (ASMB) reflects market revenue expectations, where the value 0.07 represents the current figure. Assembly Biosciences (ASMB) develops targeted drugs against hepatitis B, the success of which depends on FDA approval. The company's scientific authority in virology ensures expert confidence. A shortage of effective therapies and support from major partners create broad opportunities for expansion.

Company Future Sales: Assembly Biosciences (ASMB) for 07/04/2022 - 11/13/2026

Summary analytical data breakdowns for Assembly Bio (ASMB)

- stock value and consensus price forecast:
Price Chart Assembly Biosciences|ASMB - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Assembly Bio|ASMB - Enterprise Value
- book capitalization information:
Net Assets per Single Share Assembly Biosciences|ASMB - Book Valuation of Business|Market Value to Book Value Ratio assemblybio.com|ASMB - Company Total Asset Base
- company liabilities and liquidity data:
Total Debt to Capital Assembly Biosciences|ASMB - Long-Term Liabilities to Capital|Short-Term Debt to Equity Assembly Biosciences Inc|ASMB - Company Total Debt|Debts to Book Capitalization Assembly Bio|ASMB - Company Long-Term Debt|Company Short-Term Debt Assembly Biosciences|Quick Liquidity Indicator assemblybio.com
- company profitability and valuation multiples indicators:
ASMB - Company Net Income|Future Profit Assembly Biosciences|ASMB - Company Value to Net Income|Forward P/E Multiple Assembly Biosciences, Inc.|ASMB - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Assembly Bio|ASMB - Operating income before deduction of amortization|Earnings per share for the last twelve months Assembly Biosciences|ASMB - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months assemblybio.com|ASMB - Expected net earnings per share growth this year|Earnings growth forecast for next year Assembly Biosciences
- revenue and sales proceeds data:
ASMB - Company Sales|Projected Sales Volume Assembly Biosciences|ASMB - Price-to-Revenue Coefficient|Forward P/S Multiple Assembly Bio
Fundamental company analysis:Assembly Biosciences
Brand item of Assembly Biosciences Inc

This indicator aggregates revenue forecast models, allowing investors to differentiate short-term volatility from long-term cash flow generation potential. When analyzing revenue expectations for Assembly Biosciences (ASMB), it should be noted that this metric reflects the effectiveness of the company's antiviral drug development strategy and the performance of its partnerships with pharmaceutical behemoths in the field of liver disease treatment.

Competing companies

Company Projected Revenue Arrowhead Pharmaceuticals (ARWR)|MIRM (mirumpharma.com) - Company Future Revenue|Projected Sales Volume DVAX (Dynavax Technologies Corp)|Projected Sales Volume Arbutus Biopharma Corp ABUS|IVA - Company Projected Revenue|Company Future Sales Gyre Therapeutics Corp. GYRE|galectintherapeutics.com (GALT) - Company Projected Revenue|GNFT - Company Future Sales|DRRX (DURECT Corp) - Projected Sales Volume|Company Expected Sales Volume Aligos ALGS|Company Projected Revenue BioVie Inc. (BIVI)|Company Future Sales Volume galmedpharma.com GLMD|Projected Sales Volume NDRA (ENDRA Life Sciences)|Hepion Pharmaceuticals Inc. - Company Projected Revenue